Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.
复制标题
DOI：
10.3389/fonc.2023.1267650
复制
发表时间：
2023
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
出现4期卵巢癌的患者，包括低级别浆液性疾病，预后很差。虽然基于铂的疗法可以提供一些反应，但这些疗法与许多副作用相关，而且往往会产生治疗耐药性。随着疾病的发展，毒副作用使患者无法接受额外的治疗路线，并将他们的选择限制在临终关怀或姑息治疗上。在此病例报告中，我们描述了一位罕见的转移性低级别浆液性卵巢癌患者，他具有一些高级别疾病的特征，曾接受过四种治疗方案，并患有肺不张、肺栓塞和肾积水。CLIA认证的从患者肿瘤中提取的有机培养物的药物敏感性分析(PARIS®TEST)确定了几种治疗方案，包括氟维斯特和依维莫司的组合。在这种治疗方案中，患者经历了7个月的病情稳定，并在死于疾病之前存活了近11个月。这一案例强调了体外药物测试作为一种新的功能精确医学方法的临床效用，以实时确定患者的个性化治疗选择，特别是那些没有从标准护理治疗中受益的患者。
Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects, and treatment resistance often develops. Toxic side effects along with disease progression render patients unable to receive additional lines of treatment and limit their options to hospice or palliative care. In this case report, we describe a patient with an unusual case of metastatic low-grade serous ovarian cancer with some features of high-grade disease who had received four previous lines of treatment and was suffering from atelectasis, pulmonary embolism, and hydronephrosis. A CLIA-certified drug sensitivity assay of an organoid culture derived from the patient’s tumor (PARIS® test) identified several therapeutic options, including the combination of fulvestrant with everolimus. On this treatment regimen, the patient experienced 7 months of stable disease and survived nearly 11 months before succumbing to her disease. This case emphasizes the clinical utility of ex vivo drug testing as a new functional precision medicine approach to identify, in real-time, personalized treatment options for patients, especially those who are not benefiting from standard of care treatments.
登录
查看更多内容
激素治疗用于治疗复发性低级别浆液性卵巢癌或腹膜癌。
影响因子：
4.7
作者：
Gershenson DM;Sun CC;Iyer RB;Malpica AL;Kavanagh JJ;Bodurka DC;Schmeler K;Deavers M
通讯作者：
Deavers M
影响因子：
7.9
作者：
通讯作者：
--
影响因子：
4.6
作者：
通讯作者：
--
DOI：
10.1158/1078-0432.ccr-21-4183
发表时间：
2022-10-14
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.7
作者：
Fader, Amanda N.;Bergstrom, Jennifer;Rose, Peter G.
通讯作者：
Rose, Peter G.